New-Onset Diabetes Mellitus Associated with Use of Protease Inhibitor
Authors: John A. Eastone
Journal: Annals of Internal Medicine (1997)

Letters15 November 1997New-Onset Diabetes Mellitus Associated with Use of Protease InhibitorJohn A. Eastone, MD and Catherine F. Decker, MDJohn A. Eastone, MDNational Naval Medical Center; Bethesda, MD 20889 and Catherine F. Decker, MDNational Naval Medical Center; Bethesda, MD 20889Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-10-199711150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The use of protease inhibitors has revolutionized the treatment of HIV infection through the ability of these drugs to decrease viral load [1]. Although these agents are fairly well tolerated, previously unrecognized adverse reactions will become more evident as the availability of the drugs improves and use becomes more widespread. New-onset diabetes mellitus has been described with several agents commonly used to manage HIV disease [2-4]. We noted a strong temporal relation between the onset of hyperglycemia and the initiation or change in protease inhibitor therapy in five HIV-infected patients.The Table 1 shows the characteristics of ...References1. Bartlett J. Protease inhibitors for HIV infection. Am J Med. 1996; 124:1086-8. Google Scholar2. Nasti G, Zanette G, Inchiostro S, Donadon V, Tirelli U. Diabetes mellitus following intravenous pentamidine administration in a patient with HIV infection. Arch Intern Med. 1995; 155:645-6. Google Scholar3. Henry K, Rathgaber S, Sullivan C, McCabe K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med. 1992; 116:53-4. Google Scholar4. Albrecht H, Stellbrink HJ, Arastéh K. Didanosine-induced disorders of glucose intolerance. Ann Intern Med. 1993;119:1050. Google Scholar5. Mellors JW, McMahon DK, Chodakewitz JA, Schleif WA, Emini EA, Condra IH. Correlation between genotypic evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiretroviral effect in treated patients [Abstract]. In: Program and Abstracts of the Fourth International Workshop on HIV Drug Resistance, 6-9 July 1995, Sardinia, Italy. Google Scholar Author, Article, and Disclosure InformationAffiliations: National Naval Medical Center; Bethesda, MD 20889 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHIVAN, AdultDiabetes and HIVEndocrine and Metabolic Emergencies in HIV/AIDSImpact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant RecipientsHIVAN, AdultInfections virales et diabète en AfriqueDiabetes and Dyslipidemia in Treated Human Immunodeficiency Virus Infection and Approaches for Cardiometabolic CareA Randomized Controlled Trial to Assess Safety, Tolerability, and Antepartum Viral Load with Increased Lopinavir/Ritonavir Dosage in PregnancyHIV and diabetesNutrition and the HIV-associated lipodystrophy syndromeThe Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic CareThe prevalence and pathogenesis of diabetes mellitus in treated HIV-infectionIssues of Prematurity and HIV InfectionPediatric antiretroviral therapyGastrointestinal and Hepatobiliary Manifestations of Human Immunodeficiency Virus InfectionEffect of HCV Infection on Glucose Metabolism in Pregnant Women with HIV Receiving HAARTHow sweet it is? Susceptibility to diabetes mellitus in HIV-1 treatmentPrevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral TherapyLipid Profile of Infected Patients Treated with Highly Active Antiretroviral Therapy in CameroonDrug-induced diabetes mellitusUnusual Thromboses Associated with Protein S Deficiency in Patients with Acquired Immunodeficiency Syndrome: Case Reports and Review of the LiteratureGuidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIVOral Glucose Tolerance and Insulin Sensitivity Are Unaffected by HIV Infection or Antiretroviral Therapy in Overweight WomenImproved Obstetric Outcomes and Few Maternal Toxicities Are Associated With Antiretroviral Therapy, Including Highly Active Antiretroviral Therapy During PregnancyProtease Inhibitor-Induced Diabetic ComplicationsTolerability and Safety of HIV Protease Inhibitors in AdultsSafety and Pharmacokinetics of Antiretroviral Therapy During PregnancyRestoration of Human Immunodeficiency Virus-1-Specific Responses in Patients Changing from Protease to Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral TherapyOlder HIV Patients Face Metabolic ComplicationsFactors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapyEffects of HIV protease inhibitor therapy on lipid metabolismHIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin DEarly Versus Delayed Antiretroviral Therapy in Patients with HIV InfectionMetabolic Complications Associated with HIV Protease Inhibitor TherapyGuidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*Mark Dybul, MD, Anthony S. Fauci, MD, John G. Bartlett, MD, Jonathan E. Kaplan, MD, and Alice K. Pau, PharmDSwitch studies: a reviewPathogenesis and Clinical Manifestations of HIV-1 InfectionHIV-Infektion und Kaposi-SarkomTratamiento antirretroviral con nelfinavir en un paciente infectado por el VIH y diabetes mellitus secundaria a indinavirIncreased serum interferon alpha in HIV-1 associated lipodystrophy syndromeBody Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase InhibitorsPharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and SimvastatinHIV Inhibitors: Problems and RealityCardiovascular Disease Risk Factors in HIV‐Infected Patients in the HAART EraGuidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmissionMetformin in an HIV-Infected Patient with Protease Inhibitor—Induced Diabetic KetoacidosisGuidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, February 5, 2001Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapyGlucose Disorders Associated with HIV and its Drug TherapyPublic Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United StatesRevised November 3, 2000Tratamiento de la lipodistrofia en pacientes con infección por el virus de la inmunodeficiencia humanaSuppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease InhibitorsDisorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency VirusSignificant Toxicities Associated with Antiretroviral TherapyUS Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States, February 25, 2000, by the PerinatalComplementary and Alternative Therapies to Manage HIV-Related SymptomsDiabetes Mellitus Associated with Recombinant Human Growth Hormone for HIV Wasting SyndromeHyperglycemia associated with protease inhibitors in HIV-1-infected patientsManagement of the Adverse Effects of Antiretroviral Therapy and Medication AdherenceCardiovascular Complications of HIVAccelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapyComplete resolution of protease inhibitor induced diabetes mellitusProtease Inhibitor-Associated Hyperglycemia in Mexican Patients with HIV InfectionHyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionHyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionHIV-Associated Lipodystrophy SyndromeLipodystrophy Syndrome in HIV InfectionFat distribution and metabolic changes in patients with HIV infectionDiabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intoleranceElevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapyInsulin Resistance in HIV Protease Inhibitor–Associated DiabetesAbnormal lipids and the acquired immunodeficiency syndrome: is there a problem and what should we do about it?New Developments in the Treatment of HIV Disease: An OverviewA review of selective infections in the adult diabeticMetabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndromeA Review of Protease Inhibitor-Induced HyperglycemiaTreatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patientsProtease inhibitor-associated hyperinsulinaemiaDiabète sucré au cours des traitements par inhibiteurs des protéases chez le patient infecté par le VIHEarly experience with protease inhibitors in human immunodeficiency virus-infected childrenKetoacidosis associated with protease inhibitor therapyExacerbated Hyperglycemia Associated with NelfinavirPharmacologic Factors Affecting Glycemic Control 15 November 1997Volume 127, Issue 10Page: 948KeywordsAdverse reactionsDiabetes mellitusDrug therapyHIV infectionsHyperglycemiaMedical risk factorsNucleosidesProtease inhibitor therapyProtease inhibitorsViral load Issue Published: 15 November 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...